US OK for GSK meningococcal vaccine protects babies, without added shots
This article was originally published in Scrip
Executive Summary
When GlaxoSmithKline set out to develop a vaccine to protect young infants from meningococcal disease caused by Neisseria meningitidis, which is rare, but deadly, the company wanted to ensure it was not burdening immunization delivery for those patients – with babies' schedule for shots already "crowded," said Dr Leonard Friedland, North American vice president of clinical and medical affairs at the firm's vaccine unit.